Akero Therapeutics Inc

Akero Therapeutics — Investor Presentation (January 2025)

71 slides from Akero Therapeutics's investor presentation, Jan 27, 2025

  1. Slide 1: Corporate Presentation: Restoring Balance. Renewing Life.

    Corporate Presentation Restoring Balance. Renewing Life. January 2025 Exhibit 99.3

  2. Slide 2: Safe Harbor and Legal Disclaimers

    Safe Harbor and Legal Disclaimers This presentation may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial condit

  3. Slide 3: EFX: Potential Best-in-Class MASH Drug with Near-Term Milestones

    HARMONY: 96-wk Ph2b study Week 96 data provided strongest reported efficacy data to date across MASH field: ≥1 stage fibrosis improvement 2 stage fibrosis improvement MASH resolution Fibrosis improvement and MASH resolution SYMMETRY: 96-wk Ph2b study Week 96 data provided first-ever report of statis

  4. Slide 4: EFX Bivalent Structure Potentially Optimal for MASH Efficacy

    EFX Bivalent Structure Potentially Optimal for MASH Efficacy, With Convenient Once-weekly Dosing Bivalent FGF21 Analog Brings: Stanislaus, S et al. (2017) Endocrinology 158(5): 1314-27; Lee, S et al. (2018) Nature 553: 501-505; Kharitonenkov, A et al. (2007) Endocrinology 148(2)774-781 High β-Klotho

  5. Slide 5: EFX Direct And Indirect Anti-fibrotic Effects

    EFX Direct And Indirect Anti-fibrotic Effects EFX Anti-Fibrotic Activity Hepatocyte Stress & Death Myofibroblast Differentiation Kupffer Cell Activation Fibrogenesis Pathogenesis of Fibrosis Bao, L et al. (2018) Br J Pharmacol 175:3379-3393; Fisher, FM et al. (2014) Gastroenterology 147:1073-1083.e6

  6. Slide 6: Key Regulatory Designations Based on EFX Therapeutic Profile

    Key Regulatory Designations Based on EFX Therapeutic Profile Fast Track (US FDA - 2021) Breakthrough Therapy (US FDA - 2022) Enables expedited development Signifies potential for substantial improvement over available therapy on clinically significant endpoints Based on Phase 2b HARMONY data PRIME (

  7. Slide 7: Comprehensive Phase 3 SYNCHRONY Program Builds on Phase 2b Data

    Fibrosis Stage F2-F3 F2-F3 F4, Compensated F4, Compensated Phase 2b 3 2b 3 N 128 1650 182 1150 Weeks 96 240 96 ~260 Phase 3 study evaluating safety & tolerability in ~700 clinically-diagnosed patients (F1 to F4, compensated) for 52 weeks Comprehensive Phase 3 SYNCHRONY Program Builds on Data from Tw

  8. Slide 8: Phase 3 SYNCHRONY Trial Designs: Histology and Real-World

    Phase 3 SYNCHRONY Trial Designs: Histology (F2-F3) and Real-World (F1-F3) Baseline Liver Biopsy Screening 12 Weeks prior to Day 1 Randomization 1:1:1 (N≈1650) EFX 28mg Placebo Total Treatment Duration: 240 Weeks EFX 50mg EFX 50mg Placebo EFX 50mg (Open Label Rollover) Primary Endpoint Safety & Toler

  9. Slide 9: Phase 3 SYNCHRONY Trial Design: Outcomes (F4, Compensated)

    Phase 3 SYNCHRONY Trial Design: Outcomes (F4, Compensated) Key Secondary Efficacy Endpoints for All Phase 3 Studies Fibrosis Markers Lipoproteins Glycemic Control Weight Change Liver Injury Markers Baseline Liver Biopsy EFX 50mg Placebo Total Treatment Duration: ~260 Weeks Week 96 Liver Biopsy Patie

  10. Slide 10: Commercial Supply Chain of API and Drug Product/Device

    Commercial Supply Chain of API and Drug Product/Device: Supply Authorized Globally for Initiated Phase 3 Studies Drug Product/Device Combination Drug Substance (API) Commercial scale High Titer E. Coli Expression Process validation complete Commercially precedented 1 mL lyo/liquid Dual Chamber Syrin

  11. Slide 11: Recent Progress, Near-Term Milestones, and Cash on Hand

    Recent Progress, Near-Term Milestones, and Cash on Hand First Patients Enrolled in Phase 3 Q4’23 Phase 2b (F2-F3) Week 96 Readout with Liver Histology Mar’24 Phase2b (F4, Compensated) Week 96 Readout with Liver Histology Jan’25 First Patient Enrolled in Phase 3 (F4, Compensated) Sep’24 Cash sufficie

  12. Slide 12: EFX: Treatment of Compensated Cirrhosis (F4) Due to MASH

    EFX: Treatment of Compensated Cirrhosis (F4) Due to MASH Statistically Significant Reversal of Cirrhosis after 96 Weeks ©2025 AKERO THERAPEUTICS.

  13. Slide 13: High Risk of Mortality Associated with Cirrhosis Due to MASH

    High Risk of Mortality Associated with Cirrhosis Due to MASH Survival Free of Liver Transplantation Follow-up (years) Cumulative Survival (%) Angulo, P et al. (2015) Gastroenterology 149:389-397 P<0.001 F4 50% ~50% 5-year mortality without liver transplant for F4 patients 40% 20% 0% 100% 80% 60% ©20

  14. Slide 14: No Compound Has Shown Statistically Significant Reversal of Cirrhosis

    1mg (n=42) 3mg (n=55) 21% 15% No Compound To Date Has Shown Statistically Significant Reversal of Cirrhosis Due to MASH in Clinical Trials 6mg (n=351 18mg (n=354) 20mg (n=37) 40mg (n=39) 14% 13% 31% 24% 25mg (n~306) 10mg (n~306) 10% 12% 2.4mg (n=47) 11% 200mg (n=76) 700mg (n=79) 8% 8% Aldafermin5 48

  15. Slide 15: Phase 2b SYMMETRY Trial Design: Compensated Cirrhosis

    Phase 2b SYMMETRY Trial Design: Compensated Cirrhosis (F4) Due to MASH with Liver Histology at 36 and 96 weeks EFX 28mg (N=57) Placebo (N=61) EFX 50mg (N=63) Screening Randomization Phase 2b Key Inclusion Criteria1 F4 MASH, Child-Pugh A T2D or 2 of 4 components of metabolic syndrome2 Phase 2b Primar

  16. Slide 16: Baseline Demographics

    Baseline Demographics Parameter (Mean) Placebo (N=61) EFX 28mg (N=57) EFX 50mg (N=63) Age (Years) 61 62 59 Sex (% Female) 62 68 70 Enhanced Liver Fibrosis (ELF) Score 10.4 10.6 10.5 Liver Stiffness by VCTE (FibroScan) (kPa) 24.7 24.1 24.5 Alanine Aminotransferase (ALT) (U/L) 40.3 40.1 38.4 Aspartate

  17. Slide 17: Patient Disposition

    11% Discontinued for Administrative Reasons1 Patient Disposition 28mg (N=41) (89% Retention) 50mg (N=46) (90% Retention) Placebo (N=47) (82% Retention) Biopsy Collected at Week 36 (N=154) Randomized & Dosed (N=181) Biopsy Collected at Week 96 (N=134) 87% Retained from Week 36 to 96 2% Discontinued D

  18. Slide 18: SYMMETRY Week 96 Main Analysis Sets

    SYMMETRY Week 96 Main Analysis Sets Analysis Set1 N Description Week 96 Liver Biopsy Analysis Set (LBAS) 134 All patients with baseline and Week 96 biopsy results Safety Set / Full Analysis Set (FAS)2 181 All randomized patients who received at least one dose of study drug 28mg (N=41) 50mg (N=46) Pl

  19. Slide 19: Unprecedented Reversal of Cirrhosis Observed in SYMMETRY with 50mg EFX

    Placebo (N=61) EFX 28mg (N=57) EFX 50mg (N=63) 12% 21% *29%* EFX 28mg N=41 EFX 50mg N=46 Placebo N=47 Fibrosis Improvement ≥1 Stage & No Worsening of MASH at Week 96 Primary Analysis1 1 All patients with baseline and Week 96 biopsies ** p<0.01, versus placebo (CMH test3) 39%** 29% 15% Unprecedented

  20. Slide 20: Improved and Durable Response Observed with Longer Treatment

    Sustained (n=6) New (n=6) Sustained (n=9) New (n=9) Sust. (n=4) New (n=3) **39%** EFX 28mg N=41 EFX 50mg N=46 Placebo N=47 29% 15% Fibrosis Improvement ≥1 Stage & No Worsening of MASH at Week 96 Sustained1 & New2 Responders Placebo (N=8) EFX 28mg (N=9) EFX 50mg (N=12) 4 (50%) 6 (67%) 9 (75%) Proport

  21. Slide 21: Baseline GLP-1 Therapy Did Not Impact Reversal of Cirrhosis

    EFX 28mg N=32 EFX 50mg N=29 Placebo N=36 45%** 28% 17% Subgroup (N=97): Patients Without GLP-1 Use at Baseline EFX 28mg N=41 EFX 50mg N=46 Placebo N=47 ** p<0.01, versus placebo (CMH test) 39%** 29% 15% All Patients with Baseline and Week 96 Biopsies (N=134) Baseline GLP-1 Therapy Did Not Impact Rev

  22. Slide 22: MASH Resolution Observed at Week 96

    EFX 28mg N=32 EFX 50mg N=40 Placebo N=34 MASH Resolution Primary Analysis1 ** p<0.01, *** p<0.001, versus placebo (CMH test) 55%** 59%*** 18% MASH Resolution Observed at Week 96 Source Data: LBAS subgroup (definitive MASH at baseline); FAS ©2025 AKERO THERAPEUTICS. Placebo (N=45) EFX 28mg (N=45) EFX

  23. Slide 23: Treatment-Emergent Adverse Events through Week 96

    Treatment-Emergent Adverse Events (TEAEs): Cumulative from Baseline through Week 96 TEAE Overview Placebo (N=61) EFX 28mg (N=57) EFX 50mg (N=63) TEAEs Leading to Death a 1 (2%) a 0 (0%) 0 (0%) Treatment-Emergent Serious Adverse Events (SAEs) 11 (18%) 15 (26%) 15 (24%) Drug-Related SAEs 0 0 0 TEAEs L

  24. Slide 24: Additional Safety Observations for 50mg EFX at Week 96

    Additional Safety Observations for 50mg EFX (Phase 3 Dose) Versus Placebo at Week 96 Bone Mineral Density 43% of 50mg EFX and 41% of placebo patients had osteopenia1 at baseline, but only 3% of 50mg EFX and 7% of placebo patients were treated with bisphosphonates Placebo-adjusted, significant relati

  25. Slide 25: Reductions in Imaging and Circulating Biomarkers of Fibrosis

    Pattern of Reductions in Imaging and Circulating Biomarkers of Fibrosis Corroborate Histological Improvement in Cirrhosis LS Mean Change From Baseline to Week 96 Source Data: FAS (non-missing values only, no imputation) ©2025 AKERO THERAPEUTICS. Liver Stiffness (%)2 -18% -8% EFX 50mg N=47 Placebo N=

  26. Slide 26: Reductions in Markers of Liver Injury Through Week 96

    (Baseline: 38-40 U/L) * p<0.05,** p<0.01, *** p<0.001, versus placebo (MMRM) Statistically Significant Reductions in Markers of Liver Injury Sustained Through Week 96 with 50mg EFX ALT (U/L) LS Mean Change from Baseline AST (U/L) LS Mean Change from Baseline *** * * ** * ** ** ** ** * ** ** ** *** *

  27. Slide 27: Significantly Improved Lipoprotein Profile at Week 96

    EFX 50mg N=47 Placebo N=49 EFX 28mg N=40 HDL Cholesterol +6** -2 +9*** ** p<0.01, *** p<0.001, versus placebo (MMRM) EFX 50mg N=47 Placebo N=49 EFX 28mg N=40 Non-HDL Cholesterol -19 -10 -21* EFX 50mg N=47 Placebo N=49 EFX 28mg N=40 Triglycerides -27* -3 -33* * p<0.05, *versus placebo (MMRM) Signific

  28. Slide 28: Significantly Improved Insulin Sensitivity at Week 96

    EFX 50mg N=45 Placebo N=48 EFX 28mg N=41 C-Peptide (%) * p<0.05, versus placebo (MMRM) -13% -1% *-18%* EFX 50mg N=46 Placebo N=49 EFX 28mg N=41 Adiponectin (%) +32% +8% 69%*** *** p<0.001, versus placebo (MMRM) Significantly Improved Insulin Sensitivity Observed at Week 96 with 50mg EFX Source Data:

  29. Slide 29: EFX First Compound Reported to Reverse Cirrhosis Due to MASH

    Aldafermin5 48 Wks / Ph2b Discontinued FGF19 1mg (n=42) 3mg (n=55) 21% 15% EFX is the First Compound that Has Been Reported to Statistically Significantly Reverse Cirrhosis Due to MASH1 Selonsertib3 48 Wks / Ph3 Discontinued ASK-1 Peg-FGF21 Pegbelfermin4 48 Wks / Ph2b Discontinued 6mg (n=351 18mg (n

  30. Slide 30: Phase 3 SYNCHRONY Outcomes Trial Design

    Phase 3 SYNCHRONY Outcomes Trial Design Baseline Liver Biopsy EFX 50mg Placebo Total Treatment Duration: ~260 Weeks Week 96 Liver Biopsy (Cohort 1) Patient Population Cirrhosis Due to MASH (F4, Compensated) Primary Histology Endpoint ≥ 1-stage fibrosis improvement and no worsening of MASH at Week 96

  31. Slide 31: Unprecedented Clinical Activity for 50mg EFX After 96 Weeks

    Unprecedented Clinical Activity for 50mg EFX After 96 Weeks ©2024 AKERO THERAPEUTICS. Completers 39% vs. 15% (24% Effect Size) Source Data: LBAS; ITT ITT 29% vs. 12% (17% Effect Size) Reversal of Cirrhosis in <2 Years p=0.009 p=0.031 With Favorable Tolerability Profile ≥1 stage improvement in fibros

  32. Slide 32: EFX: Treatment of Pre-Cirrhotic MASH (F2-F3)

    EFX: Treatment of Pre-Cirrhotic MASH (F2-F3) Statistically Significant Effects after 96 Weeks 1-Stage Fibrosis Improvement MASH Resolution Fibrosis Improvement AND MASH Resolution 2-Stage Fibrosis Improvement ©2025 AKERO THERAPEUTICS.

  33. Slide 33: HARMONY Trial Design: Pre-Cirrhotic MASH

    HARMONY Trial Design: Pre-Cirrhotic (F2-F3) MASH with Liver Histology at 24 and 96 weeks Screening Randomization EFX 28mg Placebo EFX 50mg Phase 2b Screening Liver Biopsy Week 24 Liver Biopsy Week 96 Liver Biopsy Week 96 Primary Analyses ≥ 1 or 2 stages fibrosis improvement & no worsening of MASH MA

  34. Slide 34: Analysis Sets

    Analysis Sets Analysis Set N Description Full Analysis Set 128 All randomized subjects Safety Set / Modified Full Analysis Set (ITT) 126 All randomized and dosed subjects1 Week 24 Liver Biopsy Analysis Set 113 All subjects with baseline and Week 24 biopsy results Week 96 Liver Biopsy Analysis Set 88

  35. Slide 35: Baseline Demographics

    Baseline Demographics Parameter (Units) Placebo (N=43) EFX 28mg (N=42) EFX 50mg (N=43) Age (Years) 55 57 52 Sex (% Female) 63 69 53 Weight (kg) 108 104 103 Type 2 Diabetes (%) 65 76 70 Fibrosis Stage (% F3)1 70 64 63 Enhanced Liver Fibrosis (ELF) Score 9.8 9.7 9.8 Pro-C32 (μg/L) (GEN 2 ELISA) 125 11

  36. Slide 36: Consensus Reading of Biopsies: Rigorous Histopathology Approach

    Consensus Reading of Biopsies: Rigorous Approach to Histopathology Based on FDA Input to Minimize Variability Different Scores Slides Prepared From Tissue Samples Score 1 Score 2 Same Score Consensus Score Adjudicated Score No Consensus Consensus Meeting Final Score QC’d and Reported to Study Portal

  37. Slide 37: Fibrosis Improvement ≥1 Stage: Significant Response at Week 96

    ***75%*** ≥1 Stage Fibrosis Improvement & No Worsening of MASH: Statistically Significant Response Observed for 50mg EFX at Week 96 Source Data: Week 96 Liver Biopsy Analysis Set (LBAS-96); Modified Full Analysis Set (ITT) EFX 28mg N=26 EFX 50mg N=28 Placebo N=34 Fibrosis Improvement ≥1 Stage & No W

  38. Slide 38: Sustained, Broad and Durable Response

    Placebo (N=29) EFX 28mg (N=14) EFX 50mg (N=16) 6 (21%) 2 (14%) 10 (63%) Proportion of Week 24 Non-Responders with New Response at Week 964,5 3 Among Week 24 responders with Week 96 biopsies 3 Among Week 24 non-responders with Week 96 biopsies 5 Not analyzed for statistical significance ≥1 Stage Fibr

  39. Slide 39: EFX Fibrosis Improvement in Context: Pre-Cirrhotic MASH

    EFX Fibrosis Improvement in Context: Pre-Cirrhotic MASH: in Fibrosis & No Worsening of MASH 1 89Bio (2023) Mar 22 Corp Pres; 2 Sagimet (2024) Aug Corp Pres; 3 Madrigal (2022) Dec 19 Press Rel; 4 Novo Nordisk (2024) Nov 1 Press Rel; 5 Loomba et al. (2024) New Engl J Med 391, 299-310; 6 Sanyal et al.

  40. Slide 40: Fibrosis Improvement Stages, Weeks 24 and 96

    Fibrosis Improvement 2 Stages & No Worsening of MASH, Weeks 24 and 96 1 All subjects with baseline and Week 24 or Week 96 biopsies ** p<0.01, *versus placebo (CMH) Placebo N=34 EFX 28mg N=26 EFX 50mg N=28 3% 31%** 36%** W24 W24 W24 Rate of 2-Stage Fibrosis Improvement Doubled from Week 24 to 96 Plac

  41. Slide 41: EFX Fibrosis Improvement in Context: ≥2 Stage Improvement

    Efruxifermin Phase 2b (F2-F3) 96 Wks / 66% F3 Consensus Readers Completers1 **36%** **31%** 3% 28mg (N=26) 50mg (N=28) Placebo (N=34) EFX Fibrosis Improvement in Context: Pre-Cirrhotic MASH: ≥2 Stage Improvement in Fibrosis & No Worsening of MASH Semaglutide Phase 2b (F2-F3) 72 Wks / 69% F3 Consensu

  42. Slide 42: Significant Response Among F3 Patients

    ≥1 Stage Fibrosis Improvement & No Worsening of MASH: Statistically Significant Response Among F3 Patients Observed for 50mg EFX 2 Stages (n=5) 1 Stage (n=1) 1 Stage (n=5) 2 Stages (n=8) 1 Stage (n=3) ***68%*** EFX 28mg N=15 EFX 50mg N=19 Placebo N=22 40% 14% *** p<0.001, versus placebo (CMH) Fibros

  43. Slide 43: Reductions in Imaging and Circulating Biomarkers of Fibrosis

    Pattern of Reductions in Imaging and Circulating Biomarkers of Fibrosis Corroborate Histological Improvement in Fibrosis Source Data: FAS (non-missing values only, no imputation) LS Mean (SE) Absolute Change From Baseline to Week 96 Liver Stiffness (VCTE, kPa) ** ** * * *** *p<0.05, **p<0.01, ***p<0

  44. Slide 44: Overlap of Imaging and Circulating Biomarkers of Fibrosis

    None4 0% Liver Stiffness2 Fibrosis1 ELF3 Liver Stiffness2 Fibrosis1 ELF3 EFX 28 mg (N=26) EFX 50 mg (N=24) Source Data: Subset of the LBAS-W96 with available data Overlap of Imaging and Circulating Biomarkers of Fibrosis at 96 Weeks Corroborate Conventional Histopathology only in EFX-treated Individ

  45. Slide 45: MASH Resolution & No Worsening of Fibrosis

    MASH Resolution & No Worsening of Fibrosis: Statistically Significant Response Observed for Both EFX Groups EFX 28mg N=26 EFX 50mg N=28 Placebo N=34 MASH Resolution & No Worsening of Fibrosis at Week 96 Primary Analysis1 1 All subjects with baseline and Week 96 biopsies ** p<0.01, versus placebo (CM

  46. Slide 46: Fibrosis Improvement and MASH Resolution

    ≥1 Stage Fibrosis Improvement and MASH Resolution: Statistically Significant Response Observed for Both EFX Groups Placebo (N=43) EFX 28mg (N=40) EFX 50mg (N=43) 7% 28%** 35%** ITT Analysis2 ** p<0.01, versus placebo (CMH) 2 Subjects with missing biopsies are imputed as non-responders **54%*** EFX 2

  47. Slide 47: Improvements in Markers of Liver Injury Through Week 96

    Statistically Significant Improvements in Markers of Liver Injury Sustained Through Week 96 Source Data: FAS ALT LS Mean Percent Change from Baseline AST LS Mean Percent Change from Baseline Baseline: 50-63 U/L Baseline: 42-57 U/L *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *

  48. Slide 48: Treatment-Emergent Adverse Events through Week 96

    Treatment-Emergent Adverse Events (TEAE) From Baseline through Week 96 TEAE Overview Placebo (N=43) EFX 28mg (N=40) EFX 50mg (N=43) TEAE Leading to Death 0 (0%) 0 (0%) 0 (0%) Serious Adverse Event (SAE) 4 (9%) 4 (10%) 7 (16%) Drug-Related SAE 0 (0%) a1 (2%)a b1 (2%)b Drug-Related TEAE Leading to Dis

  49. Slide 49: Safety Overview

    Safety Overview Blood Pressure No statistical difference versus placebo in systolic & diastolic BP at week 96 Markers of Liver Function and Hemostasis Remained stable, including platelets, bilirubin, INR1, MELD2 and CP3 score Progression to Cirrhosis Balanced across dose groups Bone Mineral Density

  50. Slide 50: Improvement in Lipoproteins, Insulin Sensitivity and Body Weight

    Improvement in Lipoproteins, Markers of Insulin Sensitivity and Body Weight After 96 Weeks, LS Mean Change From Baseline Source Data: FAS, non-missing values only, no imputation Non-HDL (% change) LDL (% change) Triglyceride (% change) HDL (% change) C-Peptide (% change) HOMA-IR (% change) Adiponect

  51. Slide 51: Take-Aways: 50mg EFX After 96 Weeks

    Fibrosis Improvement Among F3 Patients5 Advanced 68%*** vs. 14% (50mg EFX vs. Placebo) Take-Aways: 50mg EFX After 96 Weeks Unprecedented 75%*** vs. 24% (50mg EFX vs. Placebo) ≥1 Stage Improvement In Fibrosis1 Deep 36%*** vs. 3% (50mg EFX vs. Placebo) 2-Stage Improvement In Fibrosis2 Week 24 to Week

  52. Slide 52: Backup Slides

    ak=ro Backup Slides

  53. Slide 53: Cohort D Trial Design: EFX with GLP-1 Receptor Agonist Therapy

    Cohort D Trial Design: EFX in Combination with GLP-1 Receptor Agonist Therapy (GLP-1) at Diabetic Doses Screening 12 Weeks EFX 50mg (N=21) Placebo (N=10) Key Inclusion Criteria Biopsy-confirmed MASH (F1-F3) Stable Dose of GLP-1a Primary Endpoint Safety & Tolerability Secondary Endpoints MRI-PDFF Fib

  54. Slide 54: Cohort D: Patient Disposition & Key Analysis Sets

    Cohort D: Week 12 Patient Disposition & Key Analysis Sets Randomized (N=32) Completed Week 12 (N=29) Randomized Not Dosed Placebo (N=1) Dosed (N=31) Full Analysis Set – All patients who were randomized and received at least one dose of study drug Safety Set - All subjects who received at least one d

  55. Slide 55: Cohort D: Baseline Demographics

    Cohort D: Baseline Demographics Parameter (Mean) Placebo (N=10) EFX 50mg (N=21) Age (Years) 55 59 Sex (% Female) 90 43 Weight (kg) 96 101 Fibrosis Stage (% F1 / F2 / F3) 40 / 10 / 50 38 / 33 / 29 Hepatic Fat Fraction by MRI-PDFF1 (%) 15 11 Pro-C32 (μg/L) 34 33 Enhanced Liver Fibrosis (ELF) Score 9.6

  56. Slide 56: Cohort D: Concomitant Diabetic Medications at Baseline

    Cohort D: Concomitant Diabetic Medications at Baseline GLP-1s Placebo (N=10) EFX 50mg (N=21) Semaglutide 60% 43% Dulaglutide 30% 52% Liraglutide 10% 5% Tirzepatide1 0% 0% Other Diabetic Medications Placebo EFX 50mg Metformin 70% 76% Insulin 30% 48% SGLT-2 20% 33% Sulfonylureas 20% 24% DPP-IV 0% 10%

  57. Slide 57: Cohort D Primary Endpoint: Safety and Tolerability

    Cohort D Primary Endpoint: Comparable Safety and Tolerability Across Both Treatment Groups Source Data: Safety Analysis Set Treatment-Emergent Adverse Event (TEAE) Overview Placebo (N=10) EFX 50mg (N=21) TEAE Leading to Death 0 (0%) 0 (0%) Drug-Related Serious Adverse Event (SAE) 0 (0%) 0 (0%)a Drug

  58. Slide 58: Cohort D: Greater Reductions in Liver Fat by MRI-PDFF

    Cohort D: Significantly Greater Relative Reductions in Liver Fat by MRI-PDFF for EFX Combined with GLP-1 than GLP-1 Alone -10% LS Mean Relative Percent Change From Baseline in Liver Fat at Week 121 *** p<0.001, versus placebo (Analysis of Covariance [ANCOVA]) *** -65% *** Source Data: MRI-PDFF Analy

  59. Slide 59: EFX Liver Fat Reduction in Context

    Madrigal Resmetirom Phase 3 QD MASLD 52 Weeks (N=318) (N=321) 100mg Pbo -48% -8% 18% Semaglutide Phase 1/2 QD MASLD 48 Weeks (N=33) (N=34) 0.4mg Pbo -58% -11% 18% Inventiva Pemvidutide Phase 1b QW MASLD 24 Weeks (N=19) (N=14) 2.4mg Pbo -76% -14% 21% Akero EFX HARMONY Phase 2b QW MASH (F2-F3) 24 Week

  60. Slide 60: More Patients Met Higher Thresholds of Liver Fat Reduction

    *** p<0.001, versus placebo (CMH) ≥ 50% Relative Reduction EFX 50mg Placebo N=16 N=10 ≥ 70% Relative Reduction 0% 88%*** EFX 50mg Placebo N=16 N=10 0% 56%** ** p<0.01, versus placebo (CMH) Normalization of Liver Fat (≤ 5%) EFX 50mg Placebo N=16 N=10 10% 88%*** *** p<0.001, versus placebo (CMH2) More

  61. Slide 61: Greater Reductions in Markers of Fibrosis

    Greater Reductions in Markers of Fibrosis for EFX Combined with GLP-1 than GLP-1 Alone Source Data: Full Analysis Set; Topline preliminary data ELF Score -0.6 ** +0.1 EFX 50mg Placebo N=21 N=10 ** p<0.01, versus placebo (MMRM) -5.2 †† -2.7 Pro-C3 (µg/L)1 EFX 50mg Placebo N=21 N=10 †† p<0.01, versus

  62. Slide 62: Greater Reductions in Markers of Liver Injury

    Greater Reductions in Markers of Liver Injury for EFX Combined with GLP-1 than GLP-1 Alone * p<0.01, versus placebo (MMRM) * p<0.01, versus placebo (MMRM) * * ALT LS Mean Change from Baseline (U/L) * * AST LS Mean Change from Baseline (U/L) Baseline: 31 U/L (Placebo); 35 U/L (EFX) Baseline: 24 U/L (

  63. Slide 63: Clinically Meaningful Improvements in HbA1c

    Clinically Meaningful Improvements in HbA1c after Only 12 Weeks Source Data: Full Analysis Set; Topline preliminary data 23% 0% -0.2 LS Mean Change in HbA1c From Baseline to Week 12 Proportion of Patients with Normalized1 HbA1c at Week 12 EFX 50mg Placebo N=21 N=10 EFX 50mg Placebo N=132 N=42 1 Norm

  64. Slide 64: EFX Complements GLP-1 by Increasing Sensitivity to Insulin

    C-Peptide -3.5% EFX 50mg Placebo N=21 N=10 -22% † † p<0.001, versus baseline (MMRM) EFX Complements GLP-1 by Increasing Sensitivity to Insulin Source Data: Full Analysis Set; Topline preliminary data +16% Adiponectin LS Mean Change From Baseline to Week 12 EFX 50mg Placebo N=21 N=10 +129% ** +129% *

  65. Slide 65: Much Greater Improvements in Lipids with EFX plus GLP-1

    *** p<0.001, versus placebo (MMRM) *** p<0.001, versus placebo Much Greater Improvements in Lipids for Patients Treated with EFX in Combination with GLP-1 than GLP-1 Alone LS Mean Percent Change From Baseline to Week 12 Source Data: Full Analysis Set; Topline preliminary data ††† p<0.01, versus base

  66. Slide 66: Weight Loss Maintained for EFX Combined with GLP-1

    Weight Loss Maintained for EFX Combined with GLP-1 Source Data: Full Analysis Set; Topline preliminary data -0.8 Body Weight, LS Mean Change at Week 12 (kg) -1.2 EFX 50mg Placebo N=21 N=10 ©2025 AKERO THERAPEUTICS.

  67. Slide 67: Cohort D Key Take-Aways

    Normalized Liver Fat Complementing GLP-1 Potential for EFX on Top of GLP-1 to be More Effective than GLP-1 Alone Improved Lipoprotein Profile Improved Fibrosis Markers Improved Glycemic Control Weight Loss Maintained Cohort D Adds to a Growing Body of Evidence for EFX’s Potential as a Cornerstone MA

  68. Slide 68: EFX's Four Attachment Points to Cellular Surface

    EFX’s Four Attachment Points to Cellular Surface May Contribute to Stronger Receptor Binding and Enhanced Efficacy Dimer structure may enable cooperative binding and enhance avidity effects EFX Single-chain FGF21 Two independent binding events preclude cooperative binding or avidity effects ©2025 AK

  69. Slide 69: Supportive Evidence for EFX's Cooperative Binding to Cell Surface

    Supportive Evidence for EFX’s Cooperative Binding to Cell Surface Single-chain FGF21 has slower association, faster and more complete dissociation Addition of Fc or 20 kDa PEG to single-chain FGF21 analog further slows association FGF21 Analog ka (1/[M*s]) kd (1/s) KD (M) EFX 1.8 x 105 3.3 x 10-6 1.

  70. Slide 70: Single FGF21 Chain Analogs Are Less Potent Than EFX

    Single FGF21 chain analogs fused to “half-life extenders” are 15- to 30-Fold Less Potent than EFX with two FGF21 chains’ or “unmodified FGF21” Monovalent Fc-RGE is less potent (higher EC50) and a partial agonist (smaller fold induction) than Monovalent RGE Likely steric hindrance effect due to Fc Ad

  71. Slide 71: Akero Therapeutics, South San Francisco, CA

    AKERO THERAPEUTICS 601 Gateway Boulevard Suite 350 South San Francisco, CA 94080

Akero Therapeutics — Investor Presentation (January 2025) on 6ix